Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.75 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | RBP4 | P02753 | 3/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032052 | 0.90 | CCR2 (0.71) | CCR2CCR5RECQLFFAR1LMNA | |
| SCHEMBL15032047 | 0.89 | CCR2 (0.84) | CCR2CCR5RBP4GPR119RECQL | |
| SCHEMBL14945908 | 0.88 | CCR2 (0.79) | CCR2CCR5LMNASCN9AADRA1A | |
| SCHEMBL12184105 | 0.87 | CCR2 (0.78) | CCR2CCR5LMNASCN9AADRA1A | |
| SCHEMBL14945907 | 0.86 | CCR2 (0.79) | CCR2CCR5RECQLFFAR1LMNA | |
| SCHEMBL12184055 | 0.86 | CCR2 (0.79) | CCR2CCR5SMOSCN9AADRA1A | |
| SCHEMBL14945719 | 0.86 | CCR2 (1.00) | CCR2CCR5GPR119LMNASCN9A | |
| SCHEMBL12184078 | 0.85 | CCR2 (0.76) | CCR2CCR5LMNASCN9AADRA1A | |
| SCHEMBL14945912 | 0.85 | CCR2 (0.70) | CCR2CCR5LMNASCN9AADRA1A | |
| SCHEMBL12184102 | 0.82 | CCR2 (0.76) | CCR2CCR5RECQLLMNASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR5 6/4885RBP4 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.